MEDIGREX
Board
1 director, last change in 2023Director, permanent representative KEMPEN Ineke
since 01-10-2013
term without a fixed end
listed in the 2025 annual accounts, filed on 27-04-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “De enige bestuurder bepaalt of zij alleen, dan wel gezamenlijk optreden. De gedelegeerden voor het dagelijks bestuur kunnen in het kader van…”deed of 16-06-2023
Permanent representatives 1
Mandates through the years
2 names, the dashed line is todayKEMPEN PHARMA
Director
Director
KEMPEN Ineke
Director
Director
BoardEarliermandate already running before its first mentionend not dated
Mandates as a list
- KEMPEN PHARMA
- Director, from 01-10-2013 to date
- Managing director, from before 01-10-2019, last mentioned in 2020
- KEMPEN Ineke
- Director, from 01-10-2013 to 16-06-2023
Control
Parent
Equity €2.7m
Profit €647,955 in 2025 (profit €224,238 in 2024)
Source: accounts KEMPEN PHARMA 2025
100%
This company
MEDIGREX
Equity €535,052
Profit €198,059 in 2025
Capital
- Capital
- €62,000
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
- KEMPEN PHARMA
Source: lists of holdings in the owners' accounts
Articles of association
deed of 16-06-2023 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- 1 director“Samenstelling raad van bestuur, 6 jaar”
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- “Titel V: Controle Controle van de vennootschap In de gevallen waar de wet dit vereist wordt de controle op de financiële toestand, op de…”